The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication
Abstract
The largest innovations within pharmaceutical development come through new compounds that have unique and novel modes of action. These innovations commonly involve expanding the protein space targeted by pharmaceutical agents. At present, information about drugs and drug targets is available online via public databases such as DrugBank and the Therapeutic Targets Database. However, this information is biased, understandably so, toward established drugs and drug-target interactions. To gain a better overview of the drug-targeted portion of the human proteome and the directions of current drug development, we developed a data set of clinical trial drug-target interactions based on CenterWatch's Drugs in Clinical Trials Database, one of the largest databases of its kind. Our curation identified 475 potentially novel clinical trial drug targets. This review aims to identify trends in drug development based on the potentially novel targets currently being explored in clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the research of small molecule drug delivery has established a solid foundation, the target of small molecule drugs accounts for only 2–5% of the human genome, so the development of other alternative therapies is necessary.293”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [293]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,648
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,232
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,832
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,557
Self-citationReorganizing the protein space at the Universal Protein Resource (UniProt)
The UniProt Consortium (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr981 · Cited by 1,223
The protein tyrosine kinase family of the human genome
Robinson, D. R., Wu, Y., & Lin, S. (2000) · Oncogene · doi:10.1038/sj.onc.1203957 · Cited by 1,179
Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,075
A transposase strategy for creating libraries of circularly permuted proteins
Mehta, M., Liu, S., & Silberg, J. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks060 · Cited by 1,042
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853
Self-citationDrugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 850
Saier, M. H. (2005) · Nucleic Acids Research · doi:10.1093/nar/gkj001 · Cited by 848
A Functional-Phylogenetic Classification System for Transmembrane Solute Transporters
Saier, M. H. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.354-411.2000 · Cited by 827
Almén, M. S., Nordström, K. J. V., Fredriksson, R., & Schiöth, H. B. (2009) · BMC Biology · doi:10.1186/1741-7007-7-50 · Cited by 632
Self-citationWebb, E. C. (1992) · Academic Press eBooks · Cited by 452
Thomsen, W. J., Grottick, A. J., Menzaghi, F., Saldana, H. R., Espitia, S. A., Yuskin, D., Whelan, K. T., Martin, M. W., Morgan, M. E., Chen, W., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133348 · Cited by 403
Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib
Domı́nguez, J. M., Fuertes, A., Orozco, L., del Monte-Millán, M., Delgado, E., & Medina, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.306472 · Cited by 249
Genomic sciences and the medicine of tomorrow
Drews, J. (1996) · Nature Biotechnology · doi:10.1038/nbt1196-1516 · Cited by 246
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
Dietrich, M. O., & Horváth, T. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3739 · Cited by 205
Garcia, J. M., Friend, J., & Allen, S. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1500-1 · Cited by 170
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies
Medina, M., Garrido, J. J., & Wandosell, F. G. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00024 · Cited by 127
Keynote review: Is declining innovation in the pharmaceutical industry a myth?
Schmid, E. F., & Smith, D. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03524-5 · Cited by 96
Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732
Kim, Y. M., An, J. J., Jin, Y. J., Rhee, Y., Soo, B., Lee, H. C., & Lim, S.-K. (2007) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.02165 · Cited by 68
Anti‐CD3 mAbs for treatment of type 1 diabetes
Kaufman, A. C., & Herold, K. C. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.933 · Cited by 60
Outlook for the next 5 years in drug innovation
Berggren, R., Møller, M., Moss, R. A., Poda, P., & Śmietana, K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3744 · Cited by 55
Fumagillin Reduces Adipose Tissue Formation in Murine Models of Nutritionally Induced Obesity
Lijnen, H. R., Frederix, L., & HOEF, B. V. (2010) · Obesity · doi:10.1038/oby.2009.503 · Cited by 48
Recent advances in the pathophysiology and pharmacological treatment of obesity
Chugh, P. K., & Sharma, S. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01347.x · Cited by 33
Toll-like receptor blocker slows beta cell death in type 1 diabetes
Aldridge, S. (2012) · Nature Biotechnology · doi:10.1038/nbt0212-124c · Cited by 14
Sources of Cancer Research Funding in the United States
McGeary, M., & Burstein, M. C. (1999) · Cited by 6
Cited by
Sorted by citations
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask‐Andersen, M., Schiöth, H. B., & Gloriam, D. E. I. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,714
Self-citationThe evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Sriram, K., & Insel, P. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111062 · Cited by 1,258
Electrostatic Interactions in Protein Structure, Folding, Binding, and Condensation
Zhou, H., & Pang, X. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00305 · Cited by 1,214
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Metadata
- Authors
- Rask-Andersen, M., Masuram, S., & Schiöth, H. B.
- Affiliations
- Department of Neuroscience and Uppsala Biomedical Center, Uppsala University, 75124 Uppsala, Sweden;
- Uppsala Monitoring Centre (SE)
- Uppsala University (SE)
- ORCID
- Schiöth, Helgi B.
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2014-01-06
- Volume
- 54
- Issue
- 1
- Pages
- 9-26
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2147241078
- Cited by
- 282
- References
- 35
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 12 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 25 · 2019: 22 · 2018: 22 · 2017: 34 · 2016: 34 · 2015: 27 · 2014: 13
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vetenskapsrådet
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- druggable genome, therapeutic target, new drug development, human proteome, treatment indications, drug development trends, DrugBank
- MeSH terms
- Alzheimer Disease, Anti-Inflammatory Agents, Antineoplastic Agents, Appetite Regulation, Clinical Trials as Topic, Evaluation Studies as Topic, Humans, Hypoglycemic Agents, Genome, Human, Databases, Factual, Proteome, G-Protein-Coupled Receptor Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
